Clinical Trials · NCT04747392
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Enrollment
- 64
- Start date
- Aug 2020
- Locations
- 1 site, China
- Primary endpoint
- PK parameters: area under the plasma concentration time curve from-time zero to time t (AUC0-t)